2304237
Project Grant
Overview
Grant Description
Sbir Phase I: Scalable Synthetic Mucin Biomaterials -The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project includes the commercialization of synthetic materials that reproduce the structures and functions of mucus gels. Nature deploys mucus to address a wide range of soft material needs, including as lubricants, adhesives, and barriers, and natural mucus is currently being investigated for filling many of these same roles in consumer products.
The synthetic mucins can impact various markets including skincare, dermatology, healthcare, and materials industries. Furthermore, synthetic analogs of mucins can advance the scientific frontiers through a better understanding of the role of mucus in digestive, respiratory, and immune systems.
The societal impacts of this project include the national economic benefits resulting from being the first to bring to market an entirely new class of biomimetic materials. This SBIR Phase I project proposes to address technical hurdles related to the sustainable scalability, biocompatibility, and tailorability of synthetic mucus biomaterials.
The current commercial manufacturers of natural mucus directly harvest the mucin biomaterials from animal mucus. Such a practice poses challenges related to purity, scalability, and reproducibility, which preclude its incorporation into many of the envisioned applications. To overcome the challenges, this project designed a synthetic mucin prototype and seeks to achieve the following goals: I) reconfigure the chemical process to reduce costs, production time, and environmental impact; II) understand the tolerance of epithelial cells to these synthetic mucins; and III) demonstrate a relationship between the chemical structure and material properties of synthetic mucins so they can be tailored to meet particular customer demands.
Taken together, these efforts will remove many of the major barriers to the commercial viability of synthetic mucins. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are not planned for this award.
The synthetic mucins can impact various markets including skincare, dermatology, healthcare, and materials industries. Furthermore, synthetic analogs of mucins can advance the scientific frontiers through a better understanding of the role of mucus in digestive, respiratory, and immune systems.
The societal impacts of this project include the national economic benefits resulting from being the first to bring to market an entirely new class of biomimetic materials. This SBIR Phase I project proposes to address technical hurdles related to the sustainable scalability, biocompatibility, and tailorability of synthetic mucus biomaterials.
The current commercial manufacturers of natural mucus directly harvest the mucin biomaterials from animal mucus. Such a practice poses challenges related to purity, scalability, and reproducibility, which preclude its incorporation into many of the envisioned applications. To overcome the challenges, this project designed a synthetic mucin prototype and seeks to achieve the following goals: I) reconfigure the chemical process to reduce costs, production time, and environmental impact; II) understand the tolerance of epithelial cells to these synthetic mucins; and III) demonstrate a relationship between the chemical structure and material properties of synthetic mucins so they can be tailored to meet particular customer demands.
Taken together, these efforts will remove many of the major barriers to the commercial viability of synthetic mucins. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding Agency
Place of Performance
Brooklyn,
New York
11232-1920
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Nomi Materials was awarded
Project Grant 2304237
worth $273,962
from in September 2023 with work to be completed primarily in Brooklyn New York United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Scalable Synthetic Mucin Biomaterials
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project includes the commercialization of synthetic materials that reproduce the structures and functions of mucus gels. Nature deploys mucus to address a wide range of soft material needs, including as lubricants, adhesives, and barriers, and natural mucus is currently being investigated for filling many of these same roles in consumer products. The synthetic mucins can impact various markets including skincare, dermatology, healthcare, and materials industries. Furthermore, synthetic analogs of mucins can advance the scientific frontiers through a better understanding of the role of mucus in digestive, respiratory, and immune systems. The societal impacts of this project include the national economic benefits resulting from being the first to bring to market an entirely new class of biomimetic materials. _x000D_ _x000D_ This SBIR Phase I project proposes to address technical hurdles related to the sustainable scalability, biocompatibility, and tailorability of synthetic mucus biomaterials. The current commercial manufacturers of natural mucus directly harvest the mucin biomaterials from animal mucus. Such a practice poses challenges related to purity, scalability, and reproducibility, which preclude its incorporation into many of the envisioned applications. To overcome the challenges, this project designed a synthetic mucin prototype and seeks to achieve the following goals: i) reconfigure the chemical process to reduce costs, production time, and environmental impact; ii) understand the tolerance of epithelial cells to these synthetic mucins; and iii) demonstrate a relationship between the chemical structure and material properties of synthetic mucins so they can be tailored to meet particular customer demands. Taken together, these efforts will remove many of the major barriers to the commercial viability of synthetic mucins._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
CT
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 6/20/24
Period of Performance
9/15/23
Start Date
8/31/24
End Date
Funding Split
$274.0K
Federal Obligation
$0.0
Non-Federal Obligation
$274.0K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2304237
Additional Detail
Award ID FAIN
2304237
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
CPRFKNKH46B7
Awardee CAGE
9C7H6
Performance District
NY-10
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $273,962 | 100% |
Modified: 6/20/24